RxDoctor Payments Data

Bob Pansick, MD

Ophthalmology · Dallas, TXNPI 1326102138

Payments from drug & device makers

$4,107in general payments, 2019–2025

Across 94 payments — averaging $43.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$2K
  • Alcon$893
  • Tarsus Pharmaceuticals, Inc.$319
  • Bausch & Lomb Americas Inc.$237
  • Glaukos Corporation$211
  • Sun Pharmaceutical Industries Inc.$170
  • plus $571 from 13 others

What the payments were for

  • Travel & lodging$97424%
  • Food & beverage$3,03374%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,107 in reported general payments places this provider in the 65th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$296,624
Medicare patients
202
Services billed
2,901

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast57$43,269
XdemvyLotilaner15$28,024
RestasisCyclosporine34$22,963
MieboPerfluorohexyloctane/Pf14$10,633
CombiganBrimonidine Tartrate/Timolol33$6,938
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol43$5,701
Cyclosporine15$4,851
Latanoprost235$1,833
Tobramycin-DexamethasoneTobramycin/Dexamethasone21$802
Dorzolamide Hcl19$354
MoxifloxacinMoxifloxacin Hcl15$294
Ketorolac Tromethamine14$239
Timolol Maleate30$198
Brimonidine Tartrate21$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$237$53,90271 claims
AbbVieRestasis, Combigan$29$29,90167 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$319$28,02415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →